PROTALIX BIOTHERAPEUTICS INC (PLX)
US74365A3095 - Common Stock
| TTM (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | 10.62M | -14.93M | -27.58M | -6.52M | -18.28M | |||
| Depreciation Amortization | 1.16M | 1.09M | 1.12M | 1.30M | 1.62M | |||
| Change In Working Capital | -18.01M | -12.02M | 9.90M | -27.13M | -6.84M | |||
| Interest Paid | 2.74M | 2.20M | 3.41M | 4.34M | 4.34M | |||
| Other non cash items | 1.82M | 860.00K | 6.28M | 6.25M | 4.14M | |||
| OPERATING CASH FLOW | -7.52M | -25.00M | -10.29M | -26.11M | -19.36M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -1.11M | -630.00K | -1.46M | -660.00K | -630.00K | |||
| Other Investing Activity | -10.31M | -4.41M | 20.38M | -19.30M | -260.00K | |||
| INVESTING CASH FLOW | -11.42M | -5.04M | 18.92M | -19.95M | -880.00K | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | N/A | 0.00 | -34.12M | -220.00K | 0.00 | |||
| Stock Issued/Repurchased | 28.75M | 8.24M | 46.20M | 46.68M | N/A | |||
| FINANCING CASH FLOW | 28.75M | 8.24M | 12.08M | 46.47M | 0.00 | |||
| Exchange Rate Effect | -117.00K | -80.00K | 10.00K | 60.00K | 230.00K | |||
| CHANGE IN CASH | 9.69M | -21.88M | 20.72M | 470.00K | -20.01M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -7.52M | -25.00M | -10.29M | -26.11M | -19.36M | |||
| Capital Expenditure | -1.11M | -630.00K | -1.46M | -660.00K | -630.00K | |||
| FREE CASH FLOW | -8.63M | -25.63M | -11.75M | -26.77M | -19.99M | |||
All data in USD